https://www.selleckchem.com/products/medica16.html
Objective Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. This study was designed to compare the cost-effectiveness of these three novel therapies in this patient population. Material and Methods Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembroliz
Like
Comment
Share
